TY  - JOUR
AU  - Dinić, Miroslav
AU  - Pecikoza, Uroš
AU  - Đokić, Jelena
AU  - Stepanović Petrović, Radica
AU  - Milenković, Marina
AU  - Stevanović, Magdalena
AU  - Filipović, Nenad
AU  - Begović, Jelena
AU  - Golić, Nataša
AU  - Lukić, Jovanka
PY  - 2018
UR  - https://dais.sanu.ac.rs/123456789/2347
AB  - The aim of this study was to test the potential of high molecular weight exopolysaccharide (EPS) produced by the putative probiotic strain Lactobacillus paraplantarum BGCG11 (EPS CG11) to alleviate inflammatory pain in Wistar rats. The EPS CG11 was isolated from bacterial surface and was subjected to Fourier-transform infrared spectroscopy (FTIR) and thermal analysis. FTIR spectra confirmed the polysaccharide structure of isolated sample, while the thermal methods revealed good thermal properties of the polymer. The antihyperalgesic and antiedematous effects of the EPS CG11 were examined in the rat model of inflammation induced by carrageenan injection in hind paw. The results showed that the intraperitoneal administration of EPS CG11 produced a significant decrease in pain sensations (mechanical hyperalgesia) and a paw swelling in a dose-dependent manner as it was measured using Von Frey anesthesiometer and plethysmometer, respectively. These effects were followed by a decreased expression of IL-1β and iNOS mRNAs in rat’s paw tissue suggesting that the antihyperalgesic and antiedematous effects of the EPS CG11 are related to the suppression of inflammatory response. Additionally, we demonstrated that EPS CG11 exhibits immunosuppressive properties in the peritonitis model induced by carrageenan. Expression levels of pro-inflammatory mediators IL-1β, TNF-α and iNOS were decreased, together with the enhanced secretion of anti-inflammatory IL-10 and IL-6 cytokines, while neutrophil infiltration was not changed. To the best of our knowledge, this is the first study which reports an antihyperalgesic effect as the novel property of bacterial EPSs. Given the high demands of pharmaceutical industry for the replacement of commonly used analgesics due to numerous side effects, this study describes a promising natural compound for the future pharmacological testing in the area.
PB  - Lausanne : Frontiers
T2  - Frontiers in Pharmacology
T1  - Exopolysaccharide Produced by Probiotic Strain Lactobacillus paraplantarum BGCG11 Reduces Inflammatory Hyperalgesia in Rats
SP  - Article 1
VL  - 9
DO  - 10.3389/fphar.2018.00001
UR  - https://hdl.handle.net/21.15107/rcub_dais_2347
ER  - 

@article{
author = "Dinić, Miroslav and Pecikoza, Uroš and Đokić, Jelena and Stepanović Petrović, Radica and Milenković, Marina and Stevanović, Magdalena and Filipović, Nenad and Begović, Jelena and Golić, Nataša and Lukić, Jovanka",
year = "2018",
abstract = "The aim of this study was to test the potential of high molecular weight exopolysaccharide (EPS) produced by the putative probiotic strain Lactobacillus paraplantarum BGCG11 (EPS CG11) to alleviate inflammatory pain in Wistar rats. The EPS CG11 was isolated from bacterial surface and was subjected to Fourier-transform infrared spectroscopy (FTIR) and thermal analysis. FTIR spectra confirmed the polysaccharide structure of isolated sample, while the thermal methods revealed good thermal properties of the polymer. The antihyperalgesic and antiedematous effects of the EPS CG11 were examined in the rat model of inflammation induced by carrageenan injection in hind paw. The results showed that the intraperitoneal administration of EPS CG11 produced a significant decrease in pain sensations (mechanical hyperalgesia) and a paw swelling in a dose-dependent manner as it was measured using Von Frey anesthesiometer and plethysmometer, respectively. These effects were followed by a decreased expression of IL-1β and iNOS mRNAs in rat’s paw tissue suggesting that the antihyperalgesic and antiedematous effects of the EPS CG11 are related to the suppression of inflammatory response. Additionally, we demonstrated that EPS CG11 exhibits immunosuppressive properties in the peritonitis model induced by carrageenan. Expression levels of pro-inflammatory mediators IL-1β, TNF-α and iNOS were decreased, together with the enhanced secretion of anti-inflammatory IL-10 and IL-6 cytokines, while neutrophil infiltration was not changed. To the best of our knowledge, this is the first study which reports an antihyperalgesic effect as the novel property of bacterial EPSs. Given the high demands of pharmaceutical industry for the replacement of commonly used analgesics due to numerous side effects, this study describes a promising natural compound for the future pharmacological testing in the area.",
publisher = "Lausanne : Frontiers",
journal = "Frontiers in Pharmacology",
title = "Exopolysaccharide Produced by Probiotic Strain Lactobacillus paraplantarum BGCG11 Reduces Inflammatory Hyperalgesia in Rats",
pages = "Article 1",
volume = "9",
doi = "10.3389/fphar.2018.00001",
url = "https://hdl.handle.net/21.15107/rcub_dais_2347"
}

Dinić, M., Pecikoza, U., Đokić, J., Stepanović Petrović, R., Milenković, M., Stevanović, M., Filipović, N., Begović, J., Golić, N.,& Lukić, J.. (2018). Exopolysaccharide Produced by Probiotic Strain Lactobacillus paraplantarum BGCG11 Reduces Inflammatory Hyperalgesia in Rats. in Frontiers in Pharmacology
Lausanne : Frontiers., 9, Article 1.
https://doi.org/10.3389/fphar.2018.00001
https://hdl.handle.net/21.15107/rcub_dais_2347

Dinić M, Pecikoza U, Đokić J, Stepanović Petrović R, Milenković M, Stevanović M, Filipović N, Begović J, Golić N, Lukić J. Exopolysaccharide Produced by Probiotic Strain Lactobacillus paraplantarum BGCG11 Reduces Inflammatory Hyperalgesia in Rats. in Frontiers in Pharmacology. 2018;9:Article 1.
doi:10.3389/fphar.2018.00001
https://hdl.handle.net/21.15107/rcub_dais_2347 .

Dinić, Miroslav, Pecikoza, Uroš, Đokić, Jelena, Stepanović Petrović, Radica, Milenković, Marina, Stevanović, Magdalena, Filipović, Nenad, Begović, Jelena, Golić, Nataša, Lukić, Jovanka, "Exopolysaccharide Produced by Probiotic Strain Lactobacillus paraplantarum BGCG11 Reduces Inflammatory Hyperalgesia in Rats" in Frontiers in Pharmacology, 9 (2018):Article 1,
https://doi.org/10.3389/fphar.2018.00001 .,
https://hdl.handle.net/21.15107/rcub_dais_2347 .